ReviewBioscience reports2026
Engineering extracellular vesicles for targeted therapeutic delivery in the heart.
Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Matrix-Bound Nanovesicles as Tissue-Specific Signaling Hubs for Immunomodulation and Precision Regenerative Medicine.Pharmaceutics · 2026Review
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a leading cause of morbidity and mortality, highlighting the need for improved therapeutic strategies. Critical to the success of therapies is efficient and targeted delivery systems. Extracellular vesicle-based delivery systems have emerged as promising candidates due to their biocompatibility and low immunogenicity. While extracellular vesicles from a wide variety of cells have been used, they have demonstrated divergent effects on the heart. The present review first summarizes the current sources of extracellular vesicles employed in heart failure therapy and their contrasting outcomes. The review then examines the view that these contrasting outcomes arise from limited cell specificity, inefficient delivery, and suboptimal cargo loading. Finally, the review discusses how these problems are being dealt with by recent advances, including genetic modification, chemical functionalization, and enhanced loading strategies. Together, these approaches highlight the potential of extracellular vesicle-based systems as precision therapeutics in cardiovascular medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.